04.07.21 -- Astellas' CMO & President Of Development Talks Best Practices
Taking biologics manufacturing to commercial scale is a complex — yet exciting — journey as you are nearing the market and patients in need. How do you minimize risk and maximize efficiency to be ready for success? Join our webinar on April 22 to learn how R-Pharm leverages our CDMO partnership to help accelerate market readiness.
Bernie Zeiher, of Astellas, took on the dual role of CMO and president of development in April 2018. Here he discusses how he adjusted to that job and some of the best practices he’s learned along the way.
How does your company’s approach to making outsourcing decisions compare with others in the industry? Data from ISR’s CDMO outsourcing models report highlights common practices that, when adopted, may improve outsourcing outcomes from drug innovators’ perspectives.
On this episode of Business of Biotech, Nevan Charles Elam, J.D., founder of Rezolute Bio, shares the company's rationale for pursuing congenital hyperinsulinism and diabetic macular edema therapeutics by leveraging monoclonal antibodies (mAbs) and discusses the company's approach to process development and manufacturing. Listen now and subscribe so you never miss an episode.
The lack of diversity in clinical trials isn’t a new problem, but in 2020 this issue rose to the forefront of the industry as a spotlight was cast on drug development as a whole due to the COVID-19 pandemic.